HomeAI · summaries
Storia in 2 fonti
Why Is Summit Therapeutics Stock Soaring Today? - Summit Therapeutics (NASDAQ:SMMT)
Summit Therapeutics partner Akeso Phase 3 HARMONi-GI1 trial shows ivonescimab outperforms durvalumab in overall survival for advanced biliary tract cancer.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
- ·
benzinga.com
Summit Therapeutics Says Ivonescimab Combination Extends Progression-Free Survival in Lung Cancer Patient
Summit Therapeutics reported positive Phase 3 trial results for ivonescimab, extending progression-free survival in lung cancer patients.
